Amylyx Pharmaceuticals, Inc. Stock News

Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%.

The decision to remove Relyvrio from the market comes after the drug failed a Phase 3 trial.

Amylyx Pharmaceuticals said on Thursday it would withdraw its amyotrophic lateral sclerosis (ALS) drug from the U.S. and Canada markets after the treatment failed in a crucial late-stage trial.

Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.

Amylyx's ALS drug failed a late-stage trial, raising questions about the future of the drug and the company itself.

Relyvrio, which is sold under the name Albrioza in Canada, is Amylyx's only product.

Amylyx Pharmaceuticals said on Friday its drug to treat a neurological disorder called ALS, or amyotrophic lateral sclerosis, failed to meet the main goal in a late-stage confirmatory study.

Investing in biotechnology (biotech) stocks is often thought of as being too risky for most investors. That's not necessarily the case.

Investors may want to jump into oversold Russell 2000 stocks. For one, after a rough outing in 2023, smaller-cap stocks are starting to come back strong.

Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.65 per share a year ago.

I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the qua

There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.

Investors with an interest in Medical - Drugs stocks have likely encountered both Amylyx Pharmaceuticals, Inc. (AMLX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best op

After being mostly down over the past three years, the biotech sector rallied hard to end 2023. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 31% in the last three months.

Stocks in the biotech sector are always going to have massive potential. Health is arguably the most important aspect of life.